G-CSF conjugates

US6555660B2 · kind B2 · utility

Assignee

• Maxygen, Inc. · US

Inventors

• Torben Lauesgaard Nissen · Summit, US
• Kim Andersen · Ridgewood, US
• Christian Hansen · Hannover, DE
• Jan Mikkelsen · Copenhagen, DK
• Hans Schambye · Copenhagen, DK

Key dates

• Filing date: Jul 11, 2001
• Grant date: Apr 29, 2003
• Expiry date: Jul 11, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.